Published in Hepatitis Weekly, April 5th, 2010
"We devised a new regimen (same-day beta/alpha 2b) to administer IFN-beta and alpha 2b on the same-day, and compared it with IFN-alpha 2b alone and IFN-alpha 2b plus ribavirin. The cases were 36 patients (26.1%) in whom ribavirin could not be used (young women, anemia, etc.) among 138 patients who underwent IFN treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.